The Fly | ADMA

ADMA Biologics

· ADMA

Dashboard

Financials

Ratios

Transcripts

Valuation

Over a week ago

Adma Biologics resumed with an Outperform at Raymond James

ADMA

Jun 10, 7:25 AM

Adma Biologics price target lowered by $4 at Mizuho

ADMA

May 7, 7:11 AM

Adma Biologics price target lowered by $3 at Canaccord, here's why

ADMA

May 7, 6:40 AM

Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M

ADMA

May 6, 5:16 PM

Adma Biologics reports Q1 EPS 19c, consensus 20c

ADMA

May 6, 5:14 PM

Adma Biologics options imply 12.3% move in share price post-earnings

ADMA

May 6, 3:25 PM

Adma Biologics announces FDA approval for Asceniv sBLA

ADMA

May 4, 7:27 AM

Adma Biologics initiated with bullish view at Canaccord, here's why

ADMA

Apr 21, 5:20 AM

Adma Biologics initiated with bullish view at Canaccord

ADMA

Apr 20, 4:20 PM

Adma Biologics price target lowered by $6 at Mizuho, here's why

ADMA

Apr 13, 10:35 AM

What You Missed On Wall Street On Friday

+28

Mar 27, 4:26 PM

Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy

+28

Mar 27, 11:53 AM

Adma Biologics call volume above normal and directionally bullish

ADMA

Mar 27, 11:45 AM

Adma Biologics responds to short seller report by Culper Research

ADMA

Mar 27, 7:37 AM

Adma Biologics falls -15.9%

ADMA

Mar 26, 12:01 PM

Adma Biologics falls -19.9%

ADMA

Mar 26, 10:00 AM

Cantor downgrades Adma Biologics on lack of clarity post short report

ADMA

Mar 26, 4:48 AM

Cantor Fitzgerald gets more bearish on Adma Biologics, downgrades shares

ADMA

Mar 25, 7:22 PM

Adma Biologics says Culper report contains 'inaccurate statements'

ADMA

Mar 25, 7:22 PM

What You Missed On Wall Street On Wednesday

+26

Mar 25, 4:27 PM

Adma Biologics falls -12.6%

ADMA

Mar 25, 12:00 PM

Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded

+24

Mar 25, 11:59 AM

What You Missed On Wall Street On Tuesday

+20

Mar 24, 4:16 PM

Culper Research short Adma Biologics, says reported growth 'a fiction'

ADMA

Mar 24, 1:39 PM

Adma Biologics announces $125M accelerated share repurchase with JPMorgan

Mar 2, 7:08 AM

Integrated Plasma-to-Product Supply Chain: ADMA's vertical integration, from plasma collection centers to a state-of-the-art manufacturing facility, ensures robust control over the entire production process and a reliable raw material supply.

Differentiated Product Portfolio: Their flagship product, ASCENIV, offers a differentiated IVIG therapy for immunocompromised patients, standing out with its specific purification steps and clinical profile.

High Barriers to Market Entry: The plasma-derived therapeutic market, characterized by immense capital requirements, stringent regulatory hurdles, and complex manufacturing, creates significant barriers that ADMA has successfully overcome.

Regulatory Approval and Compliance Risks: Delays or failure to obtain regulatory approvals for new products or indications, and ongoing compliance with strict regulatory requirements for existing products and manufacturing facilities, could impact ADMA's ability to market or produce its therapies.

Plasma Supply Chain Dependence Risks: ADMA's core business relies heavily on the availability and quality of human plasma. Disruptions in plasma collection, whether due to donor availability, regulatory changes, or operational issues at collection centers, could severely impact manufacturing capacity and revenue.

Market Competition and Pricing Pressures Risks: The market for plasma-derived therapies is highly competitive, with established players. ADMA faces risks from competitor products, pricing pressure, and challenges in securing market share or favorable reimbursement terms.